P028 Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?

Abstract Background Biologic drugs are highly effective for inflammatory bowel disease (IBD) management but key drivers of costs care especially when administered intravenously (IV). Availability subcutaneous (SC) formulations has increased convenience patients and improved access to at the cost revenue health services. The aim this study was evaluate economic impact transitioning a tertiary centre IBD cohort from IV SC biologic administration assess implications stakeholders. Methods A retrospective analysis all that received infliximab or vedolizumab in outpatient infusion tertiary, between July 2019 June 2021 undertaken. Data were extracted electronic medical records, pharmacy dispensing systems hospital business intelligence unit. An theoretical financial/capacity transition model estimated under two scenarios, using random 10% 30% patient cohort. Results Transitioning our would result loss $2,732,123.75, comprised $1,463,003.75 Weighted Inlier Equivalent Separation (WIES) $1,269,120 drug procurement revenue. However, it ease capacity by up 5256 hours. Conclusion results centres substantial savings state governments; however, switching IV-biologic generated WIES Alternative funding models required achieve sustainability reduce reliance on income.